GLP-1 and metabolic research peptides

This category holds the incretin-receptor agonists and metabolic compounds in our catalog: retatrutide, tirzepatide and 5-Amino-1MQ. Each ships from Canada as lyophilised research material, sold for laboratory use, with a third-party certificate of analysis published for the lot you receive.

Tirzepatide is a dual agonist at the GIP and GLP-1 receptors and the most heavily trialled compound we carry. Its SURPASS and SURMOUNT phase 3 programmes are published, and it is approved by the FDA as Mounjaro and Zepbound. Retatrutide adds the glucagon receptor to make a triple agonist; its phase 2 results appeared in 2023 and the first phase 3 results in 2026, and no regulator has completed a review. What we sell is research material, not those medicines.

5-Amino-1MQ sits here for its subject rather than its chemistry. It is a small-molecule NNMT inhibitor, not a peptide, and its literature is preclinical: cell culture and rodent models of NAD+ metabolism and fat-cell biology, with no published human trials.

Each product page sets out the CAS number, formula, molecular weight and storage temperature, and summarises how far the published evidence on that compound actually reaches.

Supplied for laboratory research use only, not for human or veterinary use. Certificates for every lot are on testing results.